All Articles

Engineering giant Stantec reports a landmark year with $6.5B revenue, hitting strategic targets early, and raises its dividend, signaling strong future growth.

Vista Gold Corp. launches a major public offering to advance its massive Mt. Todd gold project in Australia, testing investor appetite for junior miners.

DelphX Capital Markets raises fresh capital for its innovative structured notes, navigating weak financials and a competitive market for hybrid securities.

With a record $411M backlog and surging revenue, Redwire's strategic pivot to defense and space comes at a high cost. Can it turn growth into profit?

Intapp's new agentic AI platform, Celeste, promises to automate complex workflows while enforcing strict compliance, tackling AI's biggest hurdle in regulated industries.

The real estate giant announced a take-private merger led by its CEO alongside results showing major growth from its Toll Brothers platform acquisition.

The building products giant posted Q4 losses but its multi-billion-dollar acquisition spree and tech focus signal a radical reshaping of the industry.

The insurance distributor posted stellar 2025 results, announcing a massive share buyback and new acquisitions to fuel its aggressive growth strategy.

After a year focused on organic growth, the environmental firm posted record results and now plans a disciplined return to acquisitions in 2026.

PROCEPT BioRobotics reports record Aquablation procedures but lowers 2026 revenue guidance, signaling a strategic shift for long-term profitability.

TaskUs announces a major refinancing and a $333M special dividend, all while navigating the dual impact of AI as both a growth engine and a headwind.

Crescent's record production and strategic acquisitions paint a complex picture for investors amid a significant earnings beat but a notable revenue miss.

Asbury Automotive nets $210M from strategic dealership sales, funneling capital into debt reduction and a massively expanded share repurchase program.

As Tennessee's hospitality sector booms, one company is integrating kitchen design and equipment supply to help restaurants open faster than ever.

The biopharma company shatters records with 51% growth in its key drug, ASCENIV, and outlines a strategic overhaul aimed at long-term market dominance.

With broadband subscribers declining and competition mounting, all eyes are on Co-CEO Mike Cavanagh to outline Comcast's strategy at a key TMT conference.

The ad-tech giant posted record revenue for 2025, but a weaker-than-expected forecast for early 2026 sent its stock tumbling. What's next?

Pennant Group posts record revenue and an aggressive 2026 outlook, but rapid expansion and regulatory headwinds present a complex path forward for the provider.

MiMedx reports record 2025 sales and a $100M buyback, but faces a major challenge from new Medicare reimbursement rules set to disrupt the wound care market.

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.